02:38:12 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:EBS from 2023-04-27 to 2024-04-26 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 08:05U:EBSNews ReleaseEmergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
2024-04-01 08:00U:EBSNews ReleaseAquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
2024-03-28 08:15U:EBSNews ReleaseEmergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN(TM) Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
2024-03-25 08:05U:EBSNews ReleaseEmergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
2024-03-06 16:31U:EBSNews ReleaseEmergent BioSolutions Reports Fourth Quarter 2023 Financial Results
2024-02-29 07:00U:EBSNews ReleaseEmergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
2024-02-21 07:00U:EBSNews ReleaseEmergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
2024-01-11 08:00U:EBSNews ReleaseEmergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax ‚ ® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
2024-01-09 07:30U:EBSNews ReleaseEmergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
2023-11-28 06:59U:EBSNews ReleaseEmergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS ¢ „ ¢ (Anthrax Vaccine Adsorbed, Adjuvanted)
2023-11-24 07:30U:EBSNews ReleaseEmergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
2023-11-08 17:38U:EBSNews ReleaseEmergent BioSolutions Reports Third Quarter 2023 Financial Results
2023-10-30 16:45U:EBSNews ReleaseUPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
2023-10-19 06:30U:EBSNews ReleaseEmergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
2023-10-16 07:00U:EBSNews ReleaseEmergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
2023-10-02 07:00U:EBSNews ReleaseEmergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
2023-08-30 05:59U:EBSNews ReleaseEmergent BioSolutions ¢ € ™ NARCAN ‚ ® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
2023-08-21 18:01U:EBSNews ReleaseKenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
2023-08-08 16:32U:EBSNews ReleaseEmergent BioSolutions Reports Financial Results for Second Quarter 2023
2023-08-08 07:15U:EBSNews ReleaseEmergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
2023-07-31 16:05U:EBSNews ReleaseEmergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga ¢ „ ¢ Treatment for Ebola
2023-07-25 06:30U:EBSNews ReleaseEmergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
2023-07-20 18:03U:EBSNews ReleaseEmergent BioSolutions Receives U.S. FDA Approval of CYFENDUS ¢ „ ¢ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
2023-06-27 07:55U:EBSNews ReleaseEmergent BioSolutions Announces CEO Transition
2023-05-15 07:58U:EBSNews ReleaseEmergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
2023-05-11 06:30U:EBSNews ReleaseEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
2023-05-09 16:05U:EBSNews ReleaseEmergent BioSolutions Reports Financial Results For First Quarter 2023